Articles tagged with Cancer Medication
Scientists developed a potential new drug that destroys cancer cells while preventing their spread to other sites in the body. The compound was tested in laboratory mice and showed promising results.
Frailty affects 5-10% of people over 70, leading to increased death rates, poor function, and hospitalizations. Screening with the FRAIL questionnaire can identify frail individuals and guide treatment with exercise, nutrition supplements, vitamin D, and reduced medications.
A Singapore research team has identified a protein enzyme, MNK kinase, as a key player in the progression of chronic myeloid leukemia (CML) to its deadly terminal stage. The researchers found that targeting this enzyme could help prevent cancer stem cells from developing drug resistance and improve patient survival.
A recent study by researchers at the University of Pennsylvania found that cancer drug shortages have left physicians unable to prescribe standard chemotherapies for a range of cancers. As a result, many doctors are forced to delay or substitute treatment, leading to increased costs and potential harm to patients.
Researchers have discovered a new oncogene, NTRK1, that drives a subset of lung cancers. A novel targeted treatment approach has been proposed, with preclinical studies showing effective silencing of mutated NTRK1 genes using specific compounds.
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are testing the safety of Nivolumab, a PD-1 receptor blocking antibody, in combination with other drugs in patients with metastatic renal cell carcinoma. The study aims to assess safety and tolerability, as well as preliminary antitumor activity.
A randomized phase III trial found sorafenib stops tumor growth and provides effective treatment for thyroid cancer patients who progress following standard therapies. The therapy also thwarts disease progression even among those whose tumors do not regress, with median progression-free survival of 10.8 months.
Researchers have discovered a new oncogene, RET rearrangement, which is present in 15.7% of lung adenocarcinoma patients and may be targeted with existing tyrosine-kinase inhibitors. This finding presents a promising treatment option for patients with this specific mutation.
Researchers found that combining ipilimumab and nivolumab led to long-lasting tumor shrinkage in over half of patients with metastatic melanoma. The combination resulted in a 50% tumor size reduction in 40% of patients, with some experiencing shrinkages of over 80% within 12 weeks.
A new drug called lambrolizumab has shown promising results in treating patients with advanced melanoma, with 77% of patients experiencing tumor response and minimal serious side effects. The treatment works by blocking a protein that allows cancer cells to hide from the immune system, reactivating an immune response to attack the cancer.
Doctors at WashU Medicine have shown that testing cervical tumors before treatment can predict whether patients will do well with standard chemotherapy. The study supports personalized medicine for cervical cancer, a tumor normally treated with a one-size-fits-all approach.
Many GPs incorrectly view nicotine as more harmful than smoke, despite understanding that smoking is riskier. This misunderstanding may influence advice on alternative nicotine products.
A new study found that only one-fifth of rheumatoid arthritis patients took their oral medications at 80% or greater. Researchers emphasize the importance of following the prescribed regimen to manage disease symptoms and prevent progression. Patients with better mental health status were more likely to adhere to their medication regimen.
Researchers at Fox Chase Cancer Center are conducting further tests on the drug nivolumab, a monoclonal antibody that targets the immune system's response to cancer. The therapy appears to produce largely manageable side effects and has shown potential in treating tumors more effectively than current treatments.
Scientists have designed nanoparticles that can flip from a sphere to a net-like structure in response to tumor signals, accumulating at the site of cancer. This new approach aims to target treatments specifically to diseased cells, overcoming current limitations.
A national survey found that adults often did not make informed medical decisions due to insufficient shared decision-making. Healthcare providers need to improve patient engagement by balancing discussions on pros and cons and regularly seeking patient input.
A recent study suggests that movie advertisements for alcohol products can influence adolescent drinking behavior and that current regulations are insufficient to restrict these placements. The authors propose rating system changes to restrict depictions of drinking in youth-rated movies.
Despite promising initial results, a breakthrough treatment for Alzheimer's disease did not show any reduction in plaque burden after extensive testing. Three independent research groups failed to confirm the efficacy of bexarotene in reversing beta amyloid plaques.
A recent study published in Cell Reports reveals how certain genes control the ratio of proteins p21 and PUMA, which determines whether tumors adapt or die when faced with p53-activating drugs. The researchers found a handful of genes that fine-tune this balance.
Researchers have developed a new drug delivery system that uses nanoparticles and siRNA to target lung cancer cells, eliminating resistance and reducing systemic damage. In laboratory tests, the system showed significant improvement in treating lung tumors, with nearly 83% of the drug delivered directly to the lungs.
Researchers successfully targeted doxorubicin to mitochondria, killing cancer cells even those with developed pumps. The study suggests this approach could work with other nucleus-targeting anti-cancer drugs.
A study published in JAMA Internal Medicine found that intensity-modulated radiotherapy (IMRT) and conformal radiotherapy (CRT) had similar morbidity and cancer control outcomes after prostatectomy. The use of IMRT did not result in significant differences in long-term gastrointestinal or urinary symptoms.
A University of Michigan Health System study found that peripherally inserted central catheters more than double the risk of blood clots in critically ill patients and those with cancer. The device is often used for IV medication delivery and has lower infection risks, but may not be suitable for all patients.
Researchers have identified Dkk1 as a key player in the development of atherosclerosis, a condition that causes arteries to become stiff and narrow, leading to impaired blood flow. Targeting Dkk1 signaling may help limit arteriosclerotic disease, according to a new study.
Scientists at Texas Biomedical Research Institute have identified four genes (TENC1, ERBB3, ACVR1B, and DGKA) that influence levels of low-density lipoprotein (LDL) cholesterol. This discovery could lead to the development of new drugs to reduce heart disease risk in humans.
A first prospective trial, CUSTOM, demonstrates that genetic analysis can assign cancer treatment for patients with three types of cancers. The study found that patients and doctors are interested in personalized medicine, but rare mutations remain a challenge.
A novel agent, (S)-YK-4-279, has been shown to halt the progression of Ewing sarcoma in rats and cause tumor regression. The agent works by blocking protein-protein interaction between cancer-causing proteins.
A new study by Penn Medicine found that most cancer doctors, patients, and the general public support cutting healthcare costs by refusing to pay for drugs without improving survival or quality of life. The survey also revealed that large numbers favored not paying for more expensive drugs when cheaper alternatives are equally effective.
A new drug has shown significant promise in extending survival when used in combination with radiation therapy for brain cancer patients. The experimental drug, KU-60019, blocks the activation of ATM kinase, leading to enhanced destruction of glioma cells.
Researchers found that a tumor-activated protein, VEGF-C, activates integrin α4β1 on lymphatic vessels in lymph node tissues, making them more attractive to metastatic tumor cells. This highlights the way tumors can have long-range effects on other parts of the body, impacting tumor metastasis or growth.
The article reports on a major examination of the status of new drugs for rare diseases, which affect 200,000 patients or fewer. Pharmaceutical companies are investing in research and marketing new medicines, driven by factors such as patient advocacy groups, venture capital firms, and government incentives.
Researchers used low doses of leukemia drug nilotinib to clear toxic proteins from mouse brains affected with Parkinson's disease and other neurodegenerative disorders. The treatment improved movement and functionality in treated mice compared to untreated ones, offering a promising therapeutic strategy for these diseases.
Researchers at Oregon Health & Science University have isolated a molecular mutation causing two rare forms of leukemia. The study suggests that patients with these conditions could be helped by existing FDA-approved drugs, paving the way for potential treatment breakthroughs.
A new study found that metformin, a commonly used diabetes drug, did not improve survival rates in older breast cancer patients with diabetes. The study, published in Diabetes Care, examined 2,361 women aged 66 or older and followed them until death or March 30, 2010.
Researchers identified immune gene signatures that predict cancer recurrence in certain breast cancer types, such as basal-like or triple negative disease. These signatures can help doctors make informed treatment decisions and may lead to valuable new strategies in personalized medicine.
Researchers at Lund University are testing an antibody-based treatment for multiple myeloma, a type of blood cancer without a cure. The antibody, BI-505, has shown promising results in cell studies and animal experiments, and a clinical trial is currently underway to test its effects on patients.
A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time. The drug, Dz13, was found to be safe and showed positive effects in reducing tumour growth and spread.
A novel high-throughput screening method has identified agents that can block EZH2 methyltransferase, a key enzyme in tumor development. This approach uses AlphaLisa technology to detect methylation and accelerates the identification of small molecule inhibitors for cancer treatment.
A study found a statistically non-significant but clinically significant benefit in adding everolimus to trastuzumab treatment for HER-2 positive early breast cancer. The combination improved clinical response rates, but not pathological response rates, suggesting benefits independent of expected molecular pathways.
A recent study has revealed the magnitude of variation in gene expression measurements within breast cancers. Combining samples from multiple biopsies from a single tumour can effectively overcome this variation for selected genes, allowing for more precise treatment tailoring and reliable predictions related to disease progression.
Researchers at Case Western Reserve University School of Medicine have identified a novel method to disrupt a common cancer pathway, suggesting a new treatment for breast, colon, melanoma and other cancers. The breakthrough was achieved by targeting a mutation in the PIK3CA gene.
Researchers found that men with prostate cancer who take statin drugs are significantly less likely to die from their cancer. The study, led by Janet L. Stanford, Ph.D., followed over 1,000 Seattle-area prostate cancer patients for almost eight years and found a 5% mortality rate among statin users versus 1% for nonusers.
Researchers at Mayo Clinic discover a protein that is overly active in every human sample of kidney cancer and find an experimental drug designed to block its activity significantly reduces tumor growth. Combining it with another drug improves effectiveness.
A comprehensive analysis of 83,399 women found SERMs significantly reduce ER-positive breast cancer incidence by 38%. The study also showed increased thromboembolic events with all SERMs except tamoxifen.
Scientists have discovered a mechanism to reactivate the tumor suppressor p53 in metastatic melanoma cells, which were previously silenced by proteins iASPP and MDM2. Treatment with a combination of small molecules JNJ-7706621 and Nutlin-3 restored p53 function and suppressed tumor growth in mice.
The increasing cost of leukemia treatments in the US is leaving many patients under- or untreated due to unaffordable care. CML experts call for a long-term solution to manage treatment costs, balancing investments from various parties.
The region faces an alarming increase in cancer rates, with more than 1.7 million cases predicted to be diagnosed by 2030 and over 1 million deaths annually. Inadequate healthcare systems, lack of access to medical care, and inadequate health insurance exacerbate the issue.
Researchers have found that the menin protein suppresses signaling in the Hedgehog pathway in endocrine organs, leading to increased cell proliferation. Inhibiting this pathway using drugs reduces tumor growth in an animal model of human MEN1 syndrome.
A study at Lund University found that drinking two or more cups of coffee daily may reduce the risk of breast cancer recurrence in patients taking Tamoxifen. Caffeine has been shown to hamper cancer cell growth and activate Tamoxifen, making it more efficient.
A study published in PLOS Medicine found that white people with a history of non-melanoma skin cancer, such as basal cell and squamous cell carcinoma, are at increased risk of developing other forms of cancer in the future. The analysis revealed a 15% to 26% higher risk for men and women, respectively.
Researchers at Moffitt Cancer Center found that a p53 deficiency can slow or delay DNA repair after radiation treatment. The study revealed that p53 regulates the expression of two enzymes, JMJD2b and SUV39H1, which control DNA folding.
A new pathway has been identified that enhances tamoxifen's effectiveness in treating basal-like breast cancer, a subtype resistant to treatment. The discovery involves targeting Cdc42 protein to restore normal function of c-Cbl and improve cancer cell death.
Researchers have discovered a new approach to weight loss by blocking blood vessels in fat tissue, leading to a significant reduction in fat mass. The study found that mice who received the cancer drug Sunitinib lost an average of 70% of their fat mass, with no impact on lean body mass.
Researchers at Karolinska Institutet developed a method to assess tamoxifen's effect on breast cancer, using mammograms. Women showing a 20% reduction in breast density have a 50% reduced risk of dying from breast cancer over 15 years.
Researchers at Ohio State University Comprehensive Cancer Center found that AS1411 reduces cancer aggressiveness by inhibiting microRNA maturation, while restoring sensitivity to fulvestrant in resistant cells. The study suggests a new strategy for treating breast cancer.
A retrospective study suggests that patients with lung cancer carrying specific HER2 mutations may experience tumor shrinkage and delayed disease progression when treated with anti-HER2 drugs. The study found 1.7% of NSCLC patients in Europe had these rare mutations, which can lead to continuous activation of the HER2 protein.
Researchers at UCLA have developed a potentially more effective treatment for triple-negative breast cancer (TNBC) using nanoscale, diamond-like particles called nanodiamonds. The new compound has been shown to decrease tumor growth and eliminate side effects of cancer treatment in mice.
Researchers identified an eight-gene signature that correlates with chemotherapy outcome in lung and breast cancer patients. The gene signature, which includes the receptor for growth factor EGF, helps predict relapse-free survival after chemotherapy.
A team of scientists at Temple University School of Medicine has identified a key molecule, GRK2, in mitochondria that contributes to the death of heart cells. The researchers found that blocking this enzyme's activity can prevent its delivery to mitochondria and reduce pro-death signaling.
James Allison's discovery of the drug ipilimumab, which blocks CTLA-4 and treats T cells not cancer, has led to a significant increase in survival rates for patients with late-stage metastatic melanoma. The AACR-CRI award recognizes his contributions to cancer immunology and builds on Dr. Lloyd Old's pioneering work in harnessing the i...